In tests, the Lung EpiCheck blood test developed by Israel’s Nucleix (reported here previously) detected 85% of early stage lung cancers among smokers and ex-smokers with a high risk for developing the disease. On low-risk individuals, the accuracy increased to 91%.

https://nucleix.com/news_and_events/nucleixs-lung-epicheck-liquid-biopsy-test-detects-85-of-early-stage-lung-cancers-in-high-risk-smokers-study-published-in-european-respiratory-journal/